Nice

News

NICE rejects Sanofi's Cablivi for rare blood disorder TTP

NICE has rejected Sanofi’s Cablivi (caplacizumab) for the rare blood disorder thrombotic thrombocytic purpura (TTP) in first draft guidance.

Views & Analysis

Teva’s Kim Innes on shaping the post-COVID future with the N...

Like all UK pharma GMs working during the COVID-19 pandemic, Teva’s Kim Innes has found herself leading her company through an unprecedented crisis in one of the worst-hit countries in the

News

NICE recommends Roche's Tecentriq in ES-SCLC following price...

NICE has said that Roche’s Tecentriq (atezolizumab) plus chemotherapy should be funded by the NHS as an option for untreated extensive-stage small-cell lung cancer (ES-SCLC) in second draft

News

NICE and Roche reach funding deal for Tecentriq in triple ne...

NICE has recommended regular NHS funding for Roche’s immunotherapy Tecentriq (atezolizumab) in tough-to-treat advanced triple negative breast cancer in final draft guidance, after a previou

News

NICE backs drugs for lymphoma and lung cancer from Roche and...

NICE has recommended NHS funding for a duo of cancer drugs, giving final guidance on new options for certain patients with follicular lymphoma and lung cancer.

Market Access

NICE backs NHS funding for Roche's Kadcyla in early breast c...

NICE has published final draft guidance recommending regular NHS funding for Roche’s Kadcyla (trastuzumab emtansine) in its newer use, for certain people with HER2-positive early breast can

NICE rejects Sanofi's Cablivi for rare blood disorder TTP

Teva’s Kim Innes on shaping the post-COVID future with the N...

NICE recommends Roche's Tecentriq in ES-SCLC following price...

NICE and Roche reach funding deal for Tecentriq in triple ne...

NICE backs drugs for lymphoma and lung cancer from Roche and...

NICE backs NHS funding for Roche's Kadcyla in early breast c...

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

Nice

Editor's Picks